Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Vorinostat

Vorinostat

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Vorinostat

83 trials tracked of Vorinostat: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 673 citations.

83Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 5 Phase 2 54 Phase 1 20 Other / NA 4
  1. Phase 3 Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL Completed · 673 cited
  2. Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) Completed · 232 cited
  3. Phase 3 Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) Completed · 215 cited
  4. Phase 3 Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Completed · 30 cited
  5. Phase 3 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed
  6. Phase 2 Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma Completed
Show 44 more trials
  1. Phase 2 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed
  2. Phase 2 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma Completed
  3. Phase 2 Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant Completed
  4. Phase 2 Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) Completed
  5. Phase 2 Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma Completed
  6. Phase 2 Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Completed
  7. Phase 2 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Completed
  8. Phase 2 The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART Completed
  9. Phase 2 Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant Completed
  10. Phase 2 A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) Completed
  11. Phase 2 Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma Completed
  12. Phase 2 Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) Completed
  13. Phase 2 Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes Completed
  14. Phase 2 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat Completed
  15. Phase 2 Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma Completed
  16. Phase 2 Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients Completed
  17. Phase 2 Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Completed
  18. Phase 2 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed
  19. Phase 2 Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment Completed
  20. Phase 2 Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Completed
  21. Phase 2 Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme Completed
  22. Phase 2 Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer Completed
  23. Phase 2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma Completed
  24. Phase 2 Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Completed
  25. Phase 2 Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Completed
  26. Phase 2 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant Completed
  27. Phase 2 Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Completed
  28. Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Completed
  29. Phase 2 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed
  30. Phase 2 Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer Completed
  31. Phase 2 Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer Completed
  32. Phase 2 Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas Completed
  33. Phase 2 Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Completed
  34. Phase 2 Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer Completed
  35. Phase 2 Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer Completed
  36. Phase 2 Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Completed
  37. Phase 2 Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma Completed
  38. Phase 2 Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma Completed
  39. Phase 2 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed
  40. Phase 2 Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma Completed
  41. Phase 2 Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Completed
  42. Phase 2 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed
  43. Phase 2 Research In Viral Eradication of HIV Reservoirs Completed
  44. Phase 2 Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors Completed

Showing the 50 most-cited and recently-updated of 83 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer
ENT (Otolaryngology) Meta-analysis
HDAC inhibitors show 0.65 pooled favorable response rate in advanced head and neck cancer HDAC Inhibitors Show Promise for Advanced Head and Neck Cancer
This meta-analysis of single-arm trials evaluated HDAC inhibitor therapy for advanced head and neck cancer. The analysis found a pooled cumu…
A review of clinical trials shows that HDAC inhibitors may help patients with advanced head and neck cancer when used in combination with ot…
Oct 8, 2026
Bevacizumab plus lomustine significantly improves progression-free survival in recurrent or refractory glioblastoma
Neurology Meta-analysis
Bevacizumab plus lomustine significantly improves progression-free survival in recurrent or refractory glioblastoma Bevacizumab Plus Lomustine Shows Potential for Glioblastoma Patients
This systematic review and network meta-analysis of randomized trials evaluated various treatments for recurrent or refractory glioblastoma.…
A combination of bevacizumab and lomustine showed a significant improvement in progression-free survival for adults with recurrent glioblast…
Frontiers Aug 20, 2026